- Email: [email protected]
[153-POS]
Abstracts / Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 5 (2015) 53–156
79
[152-POS]
[153-POS]
Measurement of placental growth factor isoform 2 in first trimester of pregnancy Pertti Hurskainen, Mikko Sairanen (PerkinElmer, Inc., Turku, Finland)
Influence of a physiotherapy protocol in maternal and fetal hemodynamics in pregnant women with preeclampsia Tawana V. Bertagnolli, Michelle S. Machado, Jackeline S. Machado, Cristine H. Ferreira, Geraldo Duarte, Ricardo C. Cavalli (Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, Brazil)
Objectives: PlGF is an angiogenic factor with placental origin that is used as biomarker in screening and diagnosis of pre-eclampsia. Our objective was to develop and characterise a PlGF isoform 2 (PlGF-2) specific automated DELFIAÒ immunoassay as a tool for evaluating the role of this isoform in pregnancy and especially in pre-eclampsia. Methods: Firstly an assay utilizing a custom antibody specific for PlGF-2 (AbD Serotec) was developed. For assay characterization cross-reactivity, precision and analytical limits were determined. Finally, a small number of first trimester serum samples were analysed to see how results compare to PlGF result run with commercial assay and how PlGF-2 is regulated in pregnancies complicated with pre-eclampsia. Results: Assay has a low, 4.4% and 0.8%, cross-reactivity against other PlGF isoforms, PlGF-1 and -3, respectively. Measuring range (7.1–3500 pg/mL), Limit of quantitation at 11pg/mL and total variation of 8.3% at 32 pg/mL level allow reliable measurement of PlGF-2. PlGF-2 concentrations were about 50% lower than concentrations yielded with commercial PlGF assay from the same samples and correlation between assays was about 60% (R[2] = 0.354). Results with a small number of serum samples showed that PlGF-2 serum levels are decreased in pre-eclampsia compared to normal pregnancies, 15.0 pg/mL vs. 32.8 pg/mL, respectively. Conclusions: A sensitive and precise PlGF-2-specific AutoDELFIAÒ immunoassay was developed and first result show that assay is suitable for measuring PlGF-2 from serum
Objectives: Pregnant women with preeclampsia, due to the complexity of the clinical frame remains at rest and such conduct leads to muscle discomfort, but no studies proving the safety and effectiveness of physical therapy protocols to improve such discomforts. To evaluate the influence of a physical therapy protocol applied in pregnant women with preeclampsia in relation to maternal and fetal hemodynamics Methods: The women were randomized to the physiotherapy group or control group, both with conducting monitoring breast through pressure curve and measure heart rate and fetal monitoring with Doppler velocimetry. The physiotherapy group had the physiotherapy exercise protocol and received guidance on appropriate to stay in bed postures and the control group received only the guidelines. Results: Data were analyzed using linear regression model with mixed effects (random and fixed effects). The data on the clinical data of the patients (age, gestational age, parity, BMI) and laboratory tests (24-h proteinuria, 24-h diuresis, creatinine, uric acid, urea, hemoglobin, bilirubin, sodium and potassium) showed no difference between groups. The results of maternal and fetal hemodynamics improved, however these changes are not clinically significant. Conclusions: We can conclude that physiotherapy protocol we used is safe for both the mother and the fetus.
Data monitoring of maternal and fetal hemodynamics Physiotherapy group
Control group
Materna hemodynamics:
Pre mean
Pos mean
SBP (mmHg) Systolic blood pressure – mmHg
141,11
139,98
Diastolic blood pressure – mmHg
82,49
IC (95%)
p Value
Pre mean
Pos mean
IC (95%)
3,405,53
0,64
137,36
141,97
-9,101,50
p Value
81,79
2,794,54
0,64
80,95
83,22
5,992,70
0,46
0,16
Average arterial pressure – mmHg
111,8
110,88
2,634,56
0.6
109,15
112,59
6,961,56
0.21
Heart rate – bpm
77,53
83,46
8.40–1.93
<0.01
85,08
82,58
4,903,93
0,83
Fetal hemodynamics:
Pre mean
Pos mean
IC (95%)
p Value
Pre mean
Pos mean
IC (95%)
Middle cerebral artery – RI
0.79
0.75
0,010,08
0.02
0.76
0.7
0,010,09
Umbilical artery – RI
0,63
0,65
0.33
0.65
0.68
samples during pregnancy. Lower concentrations of PlGF-2 seem to indicate higher risk for pre-eclampsia. Additional research and larger sample sets are required to conclude the role of PlGF-2 isoform in pre-eclampsia. Disclosures: P. Hurskainen: Employee of PerkinElmer, Inc. M. Sairanen: Employee of PerkinElmer, Inc. doi:10.1016/j.preghy.2014.10.158
0,090,03
0,070,05
p Value 0,03 0.77
Disclosures: T.V. Bertagnolli: None. M.S. Machado: None. J.S. Machado: None. C.H. Ferreira: None. G. Duarte: None. R.C. Cavalli: None. doi:10.1016/j.preghy.2014.10.159
79
[152-POS]
[153-POS]
Measurement of placental growth factor isoform 2 in first trimester of pregnancy Pertti Hurskainen, Mikko Sairanen (PerkinElmer, Inc., Turku, Finland)
Influence of a physiotherapy protocol in maternal and fetal hemodynamics in pregnant women with preeclampsia Tawana V. Bertagnolli, Michelle S. Machado, Jackeline S. Machado, Cristine H. Ferreira, Geraldo Duarte, Ricardo C. Cavalli (Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, Brazil)
Objectives: PlGF is an angiogenic factor with placental origin that is used as biomarker in screening and diagnosis of pre-eclampsia. Our objective was to develop and characterise a PlGF isoform 2 (PlGF-2) specific automated DELFIAÒ immunoassay as a tool for evaluating the role of this isoform in pregnancy and especially in pre-eclampsia. Methods: Firstly an assay utilizing a custom antibody specific for PlGF-2 (AbD Serotec) was developed. For assay characterization cross-reactivity, precision and analytical limits were determined. Finally, a small number of first trimester serum samples were analysed to see how results compare to PlGF result run with commercial assay and how PlGF-2 is regulated in pregnancies complicated with pre-eclampsia. Results: Assay has a low, 4.4% and 0.8%, cross-reactivity against other PlGF isoforms, PlGF-1 and -3, respectively. Measuring range (7.1–3500 pg/mL), Limit of quantitation at 11pg/mL and total variation of 8.3% at 32 pg/mL level allow reliable measurement of PlGF-2. PlGF-2 concentrations were about 50% lower than concentrations yielded with commercial PlGF assay from the same samples and correlation between assays was about 60% (R[2] = 0.354). Results with a small number of serum samples showed that PlGF-2 serum levels are decreased in pre-eclampsia compared to normal pregnancies, 15.0 pg/mL vs. 32.8 pg/mL, respectively. Conclusions: A sensitive and precise PlGF-2-specific AutoDELFIAÒ immunoassay was developed and first result show that assay is suitable for measuring PlGF-2 from serum
Objectives: Pregnant women with preeclampsia, due to the complexity of the clinical frame remains at rest and such conduct leads to muscle discomfort, but no studies proving the safety and effectiveness of physical therapy protocols to improve such discomforts. To evaluate the influence of a physical therapy protocol applied in pregnant women with preeclampsia in relation to maternal and fetal hemodynamics Methods: The women were randomized to the physiotherapy group or control group, both with conducting monitoring breast through pressure curve and measure heart rate and fetal monitoring with Doppler velocimetry. The physiotherapy group had the physiotherapy exercise protocol and received guidance on appropriate to stay in bed postures and the control group received only the guidelines. Results: Data were analyzed using linear regression model with mixed effects (random and fixed effects). The data on the clinical data of the patients (age, gestational age, parity, BMI) and laboratory tests (24-h proteinuria, 24-h diuresis, creatinine, uric acid, urea, hemoglobin, bilirubin, sodium and potassium) showed no difference between groups. The results of maternal and fetal hemodynamics improved, however these changes are not clinically significant. Conclusions: We can conclude that physiotherapy protocol we used is safe for both the mother and the fetus.
Data monitoring of maternal and fetal hemodynamics Physiotherapy group
Control group
Materna hemodynamics:
Pre mean
Pos mean
SBP (mmHg) Systolic blood pressure – mmHg
141,11
139,98
Diastolic blood pressure – mmHg
82,49
IC (95%)
p Value
Pre mean
Pos mean
IC (95%)
3,405,53
0,64
137,36
141,97
-9,101,50
p Value
81,79
2,794,54
0,64
80,95
83,22
5,992,70
0,46
0,16
Average arterial pressure – mmHg
111,8
110,88
2,634,56
0.6
109,15
112,59
6,961,56
0.21
Heart rate – bpm
77,53
83,46
8.40–1.93
<0.01
85,08
82,58
4,903,93
0,83
Fetal hemodynamics:
Pre mean
Pos mean
IC (95%)
p Value
Pre mean
Pos mean
IC (95%)
Middle cerebral artery – RI
0.79
0.75
0,010,08
0.02
0.76
0.7
0,010,09
Umbilical artery – RI
0,63
0,65
0.33
0.65
0.68
samples during pregnancy. Lower concentrations of PlGF-2 seem to indicate higher risk for pre-eclampsia. Additional research and larger sample sets are required to conclude the role of PlGF-2 isoform in pre-eclampsia. Disclosures: P. Hurskainen: Employee of PerkinElmer, Inc. M. Sairanen: Employee of PerkinElmer, Inc. doi:10.1016/j.preghy.2014.10.158
0,090,03
0,070,05
p Value 0,03 0.77
Disclosures: T.V. Bertagnolli: None. M.S. Machado: None. J.S. Machado: None. C.H. Ferreira: None. G. Duarte: None. R.C. Cavalli: None. doi:10.1016/j.preghy.2014.10.159